$3.6 Million to Study Adverse Effects of Genome EditingNews
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.
A drug could help slow the progression of some advanced ovarian cancers and extend the time that patients show no signs of disease, according to new clinical trial results.
The chemical company BASF has attained a global, non-exclusive licensing agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cpf1 genome editing technology to improve products in agricultural and industrial microbiology applications.
Aequatus - a new bioinformatics tool developed at Earlham Institute (EI) - is helping to give an in-depth view of syntenic information between different species, providing a system to better identify important, positively-selected, and evolutionarily-conserved regions of DNA.
The precision medicine platform is 1,000 times more sensitive than conventional screening methods and can detect signs of antibiotic resistance.READ MORE
Researchers at the Wellcome Sanger Institute have created the first comprehensive summary of all genes known to be involved in human cancer, the "Cancer Gene Census".READ MORE
New details revealed of how a naturally occurring hormone can boost memory in aging mice, laying the groundwork for staving off this form of memory loss in people.READ MORE
The normal function of a gene associated with the brain diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has been determined.